Direct measurement of engineered cancer mutations and their transcriptional phenotypes in single cells
Open Access
- 11 September 2023
- journal article
- research article
- Published by Springer Nature in Nature Biotechnology
- Vol. 42 (8) , 1254-1262
Abstract
Genome sequencing studies have identified numerous cancer mutations across a wide spectrum of tumor types, but determining the phenotypic consequence of these mutations remains a challenge. Here, we developed a high-throughput, multiplexed single-cell technology called TISCC-seq to engineer predesignated mutations in cells using CRISPR base editors, directly delineate their genotype among individual cells and determine each mutation’s transcriptional phenotype. Long-read sequencing of the target gene’s transcript identifies the engineered mutations, and the transcriptome profile from the same set of cells is simultaneously analyzed by short-read sequencing. Through integration, we determine the mutations’ genotype and expression phenotype at single-cell resolution. Using cell lines, we engineer and evaluate the impact of >100 TP53 mutations on gene expression. Based on the single-cell gene expression, we classify the mutations as having a functionally significant phenotype.Keywords
Funding Information
- U.S. Department of Health & Human Services | National Institutes of Health (R01 HG006137, R33 CA247700, R33 CA278469)
This publication has 42 references indexed in Scilit:
- ClinVar: public archive of interpretations of clinically relevant variantsNucleic Acids Research, 2015
- Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2Genome Biology, 2014
- HTSeq—a Python framework to work with high-throughput sequencing dataBioinformatics, 2014
- Analysis of TP53 Mutation Status in Human Cancer Cell Lines: A ReassessmentHuman Mutation, 2014
- Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteinsGenome Research, 2014
- GSVA: gene set variation analysis for microarray and RNA-Seq dataBMC Bioinformatics, 2013
- STAR: ultrafast universal RNA-seq alignerBioinformatics, 2012
- Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapyProceedings of the National Academy of Sciences, 2006
- Lack of Correlation between p53-Dependent Transcriptional Activity and the Ability to Induce Apoptosis among 179 Mutant p53sCancer Research, 2005
- In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2Science, 2004